English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Human 60-kDa lysophospholipase contains an N-terminal l-asparaginase domain that is allosterically regulated by l-asparagine.

Karamitros, C. S., & Konrad, M. (2014). Human 60-kDa lysophospholipase contains an N-terminal l-asparaginase domain that is allosterically regulated by l-asparagine. The Journal of Biological Chemistry, 289(19), 12962-12975. doi:10.1074/jbc.M113.545038.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0019-B623-3 Version Permalink: http://hdl.handle.net/11858/00-001M-0000-0027-CF1C-E
Genre: Journal Article

Files

show Files
hide Files
:
2032452.pdf (Publisher version), 4MB
Name:
2032452.pdf
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-
:
2032452_Suppl.xlsx (Supplementary material), 26KB
Name:
2032452_Suppl.xlsx
Description:
-
Visibility:
Public
MIME-Type / Checksum:
application/vnd.openxmlformats-officedocument.spreadsheetml.sheet / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Creators

show
hide
 Creators:
Karamitros, C. S.1, Author              
Konrad, M.1, Author              
Affiliations:
1Research Group of Enzyme Biochemistry, MPI for Biophysical Chemistry, Max Planck Society, ou_578612              

Content

show
hide
Free keywords: -
 Abstract: The structural and functional characterization of human enzymes that are of potential medical and therapeutic interest is of prime significance for translational research. One of the most notable examples of a therapeutic enzyme is l-asparaginase, which has been established as an antileukemic protein drug for more than four decades. Up until now, only bacterial enzymes have been used in therapy despite a plethora of undesired side effects mainly attributed to the bacterial origins of these enzymes. Therefore, the replacement of the currently approved bacterial drugs by human homologs aiming at the elimination of adverse effects is of great importance. Recently, we structurally and biochemically characterized the enzyme human l-asparaginase 3 (hASNase3), which possesses l-asparaginase activity and belongs to the N-terminal nucleophile superfamily of enzymes. Inspired by the necessity for the development of a protein drug of human origin, in the present study, we focused on the characterization of another human l-asparaginase, termed hASNase1. This bacterial-type cytoplasmic l-asparaginase resides in the N-terminal subdomain of an overall 573-residue protein previously reported to function as a lysophospholipase. Our kinetic, mutagenesis, structural modeling, and fluorescence labeling data highlight allosteric features of hASNase1 that are similar to those of its Escherichia coli homolog, EcASNase1. Differential scanning fluorometry and urea denaturation experiments demonstrate the impact of particular mutations on the structural and functional integrity of the l-asparaginase domain and provide a direct comparison of sites critical for the conformational stability of the human and E. coli enzymes.

Details

show
hide
Language(s): eng - English
 Dates: 2014-03-222014-05-09
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: Peer
 Identifiers: DOI: 10.1074/jbc.M113.545038
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: The Journal of Biological Chemistry
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 289 (19) Sequence Number: - Start / End Page: 12962 - 12975 Identifier: -